drugset / Trial / NCT00140218
R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis
Phase 1/2
Completed
30 enrolled
Bennett, James P., Jr., M.D., Ph.D.
University of Pittsburgh · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The hypothesis of this study is that treatment with R(+) pramipexole at 30 mg/day will alter the slope of decline in ALS functional rating scale over the course of 6 months. ALS patients at an early stage of disease will be observed for 3 months after enrollment and then treated with drug for 6 months.
Timeline
- Start
- 2005-08
- Primary completion
- 2007-01
- Completion
- 2006-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pramipexole | Unknown | 10 mg | Oral |